Loading...
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with ref...
Na minha lista:
| Udgivet i: | BMC Nephrol |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501341/ https://ncbi.nlm.nih.gov/pubmed/28683788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-017-0644-0 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|